Newsroom

Sorted by: Latest

-

INVESTOR NOTICE: Eos Energy Enterprises, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO--(BUSINESS WIRE)--The Eos Energy complaint alleges that Eos Energy was unable to achieve the ramp in production and capacity utilization required to achieve guidance....
-

INVESTOR NOTICE: Snowflake Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO--(BUSINESS WIRE)--The case alleges Snowflake misled investors about revenue headwinds from product changes....
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO--(BUSINESS WIRE)--The case alleges Boston Scientific misled investors about its US EP segment's growth and competitive risks....
-

Nebius Signs New AI Infrastructure Agreement with Meta

AMSTERDAM--(BUSINESS WIRE)--Nebius Group N.V. (NASDAQ: NBIS), the AI cloud company, today announced a new long-term AI infrastructure supply agreement with Meta, strengthening the collaboration between the companies. Under the five-year agreement, Nebius will provide $12 billion of dedicated capacity across multiple locations, based on one of the first large-scale deployments of the NVIDIA Vera Rubin platform. Nebius will deliver this capacity starting early 2027. Furthermore, in connection wit...
-

85% of Banks’ Corporate Clients Plan to Engage With a Non-Bank Financial Institution Within the Next Year as Competition With Private Capital Intensifies

PARIS--(BUSINESS WIRE)--Corporate and investment banks face competition from non‑banks as client expectations rise and technology initiatives fail to live up to expectations....
-

APRIL 3RD LAWSUIT DEADLINE: Investors who lost over $100,000 with Richtech Robotics Inc. (NASDAQ: RR) with purchases between January 27 and 29, 2026 should contact the Shareholders Foundation

SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announces that a deadline is coming up on April 03, 2026, in the lawsuit pending for certain investors in Richtech Robotics Inc. (NASDAQ: RR) shares. Investors who purchased shares of Richtech Robotics Inc. (NASDAQ: RR) between January 27, 2026 and 12:00 p.m. EST on January 29, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline: April 03, 2026. NASDAQ: RR investors should conta...
-

NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program....
-

Alto Neuroscience Announces $120 Million Private Placement Financing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing...